Analyst firms · Jefferies · NKTR

Jefferies NKTR price target and rating history

Nektar Therapeutics (NKTR) · Health Care

Jefferies rates Nektar Therapeutics (NKTR) Buy with a $2 price target, as of its latest action on Apr 11, 2025. It has published 4 rating actions on NKTR since May 2022, including 2 upgrades and 1 downgrade. Across 5 firms with a NKTR price target in the last 12 months, the median target is $102.

Current rating

Buy

Price target

$2

Median target, all firms

$102

Actions on NKTR

4

Jefferies price target on NKTR

Every Jefferies rating on NKTR

• Apr 11, 2025
  UpgradeJefferies upgrades to Buy from Hold, price target $2
• May 10, 2023
  UpgradeJefferies upgrades to Hold from Underperform, price target $1.50 to $1
• Feb 24, 2023
  DowngradeJefferies downgrades to Underperform from Hold, price target $3.20 to $1.50
• May 31, 2022
  ResumeJefferies resumes coverage at Hold, price target $12 to $4

How other firms rate NKTR

Each firm's latest rating and stated target in the last 12 months.

Questions about Jefferies and NKTR

What is Jefferies's price target for NKTR?

Jefferies's latest stated price target for Nektar Therapeutics (NKTR) is $2, from its action on Apr 11, 2025.

What is Jefferies's rating on NKTR?

Jefferies rates NKTR Buy, a bullish rating, as of Apr 11, 2025.

When did Jefferies last change its view on NKTR?

On Apr 11, 2025, Jefferies upgrades to Buy from Hold, price target $2.

How does Jefferies's NKTR target compare with other analysts?

Across 5 firms with a NKTR price target in the last 12 months, the median target is $102.

More NKTR rating histories

• Leerink Partners3
• TD Cowen3
• BTIG3
• Oppenheimer3

All Jefferies ratingsNKTR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.